Research and Patents Status of Selected Phytochemicals Against Cancer: How Close and How Far?

BACKGROUND

Cancer is a global health issue and economic burden with a continuous increase in incidence and mortality. Over the years, the underlying molecular mechanism of cancers was thoroughly researched, leading to multiple drugs' development. Unfortunately, most drugs have some serious drawbacks, such as therapy resistance and toxicity. Epidemiological studies have shown that a diet rich in fruits and vegetables has cancer prevention properties, which shifted the attention to the potential role of phytochemicals in anti-carcinogenic activity.

OBJECTIVE

To review the present status of phytochemicals research and patents in cancer prevention and chemosensitization.

METHODS

We explored the relevant published articles and patents to review the phytochemicals showing cancer preventive role in preclinical settings from 1997 onwards.

RESULTS

We summarise the role of phytochemicals on anti-carcinogenic, anti-inflammatory, antiproliferative, anti-metastatic, and pro-apoptotic activities in both in vitro and in vivo. Thus, phytochemicals might be an excellent chemosensitizing agent against chemoresistant cells and possibly one of the safest and most effective options for cancer therapy. However, one of the limitations of phytochemicals is their poor bioavailability and rapid excretion. Several analogs have been introduced to increase bioavailability, better biological efficacy, absorption, and retention. In fact, various phytochemicals and their analogs have been patented for their anti-cancerous properties.

CONCLUSION

This mini-review discusses various phytochemicals and their anti-cancerous and chemosensitizing roles. Due to their clinical relevance, recent trends in phytochemical extraction and exploration have shown that more and more phytochemicals are being patented.

Direct Z-Scheme AgBr/β-MnO2 Photocatalysts for Highly Efficient Photocatalytic and Anticancer Activity

The preparation of visible light-responsive efficient photocatalysts for removing organic contaminants from water and killing cancer cells has gotten a lot of attention due to the growing global concern. In this study, we have successfully fabricated an efficient AgBr/β-MnO₂ nanocomposite via a facile deposition and precipitation method at room temperature. Techniques such as XRD, SEM-EDS, TEM, DRS, PL, EIS, ESR, and FTIR were used to determine the crystalline, structural, morphological, optical, and other properties. The SEM and TEM analyses reveal that AgBr NPs are decorated on the surface of β-MnO₂, which possesses rods with a sphere-like structure for AgBr/β-MnO₂. The EDX analysis confirms the existence of Mn, O, Ag, and Br elements in the nanocomposites without an extra peak, indicating that the synthesized samples are highly pure. The high photocatalytic performance of AgBr/β-MnO₂ could be attributed to the formation of Ag NPs and the construction of the Z-scheme heterojunction between AgBr and β-MnO₂. This may enhance fast light absorption and efficient photogenerated (e-/h+) pairs, as indicated by EIS and photoluminescence measurements, which in turn achieved high activity for the decomposition of MB (97%, in 12 min), RhB (98.9%, in 9 min), and paracetamol (80%, in 180 min), respectively. The kinetic model study proposed that the first-order model showed a better fit than the zero- and second-order for the photocatalytic decolorization of RhB dye. XRD analysis of 0.2 AgBr/β-MnO₂ before and after recycling confirms the high stability of the catalyst. HPLC results showed that no detectable by-products are produced through the decomposition of paracetamol. Interestingly, 0.2 AgBr/β-MnO₂ nanocomposites showed visible light-induced anticancer activity against A549 cancer cell lines. The mechanistic degradation pathway has been proposed using the involvement of active species like superoxide radicals (^-•O₂) and photoinduced holes (h⁺). The proposed work focuses on synthesizing effective photocatalysts in a less hazardous environment with superior biological activity.

Aflatoxin B1 Induced Structural and Conformational Changes in Bovine Serum Albumin: A Multispectroscopic and Circular Dichroism-Based Study

Aflatoxin B₁ (AFB₁) is a mutagen that has been categorized as a group 1 human carcinogen by the International Agency for Research on Cancer. It is produced as a secondary metabolite by soil fungi Aspergillus flavus and Aspergillus parasiticus . Here, in this study, the effect of AFB₁ on the structure and conformation of bovine serum albumin (BSA) using multispectroscopic tools like fluorescence spectroscopy, ultraviolet-visible absorption spectroscopy, and circular dichroism spectropolarimetry has been ascertained. Ultraviolet absorption spectroscopy revealed hyperchromicity in the absorption spectra of BSA in the presence of AFB₁. The binding constant was calculated in the range of 10⁴ M^-1, by fluorescence spectroscopy suggesting moderate binding of the toxin to BSA. The study also confirms the static nature of fluorescence quenching. The stoichiometry of binding sites was found to be unity. The competing capability of warfarin for AFB₁ was higher than ibuprofen as calculated from site marker displacement assay. Förster resonance energy transfer confirmed the high efficiency of energy transfer from BSA to AFB₁. Circular dichroism spectropolarimetry showed a decrease in the α-helix in BSA in the presence of AFB₁. The melting temperature of BSA underwent an increment in the presence of a mycotoxin from 62.5 to 70.3 °C. Molecular docking confirmed the binding of AFB₁ to subdomain IIA in BSA.

Ligand substituent effect on the cytotoxicity activity of two new copper(ii) complexes bearing 8-hydroxyquinoline derivatives: validated by MTT assay and apoptosis in MCF-7 cancer cell line (human breast cancer)

In this study, we have examined the effect of ligand substituent on the structure-cytotoxicity relationships of the MCF-7 cancer cell line (human breast cancer), by two copper(ii) complexes {[Cu(qmbn)(Hqmba)(q)]·NO3·2H2O} (1) and {[Cu(Hqmba)2(q)]·NO3·2H2O} (2) (where, qmbn = 2-(quinolin-8-yloxy)(methyl) benzonitrile (L1); Hqmba = 2-((quinolin-8-yloxy)methyl)benzoic acid (L2) and q = quinolin-8-olate). The structural analysis reveals that both the complexes exhibit distorted octahedral (CuN3O3) configuration which is further corroborated by density functional theory (DFT) calculations. The cytotoxicity impact of ligands (L1 and L2) and complexes (1 and 2) was screened against the MCF-7 cell line (human breast cancer). The MTT assay uptake indicated that the presence of -COOH functionality in complex 2 leads to higher cytotoxicity (lower IC50) than that observed for complex 1 containing a -CN group. This could be due to the strong H-bonding forming propensity of the carboxylic acids. Incubation of MCF-7 cancer cells with IC50 concentrations of 1 and 2 promoted cellular detachments via nuclear condensation and membrane destabilization followed by apoptosis as a result of metal-assisted generation of reactive oxygen species. Flow cytometry analysis showed that 1 and 2 might prompt early apoptosis in MCF-7 cells as the maximum percentage of cells appeared in the LR quadrant. Furthermore, mRNA expression analysis confirmed that both the complexes induced apoptosis in MCF-7 cells. Comparative mRNA expression analysis of complexes with their respective ligands also confirmed the enhanced apoptotic behavior of complexes. Furthermore, molecular docking studies of the complexes have also been performed with the active site of EGFR kinase receptors (major target for any cancer causing agent) due to similar analogues with FDA-approved EGFR inhibitors in order to rationalize its promising cytotoxicity activity.